At the completion of this activity participants should be able to:
Explain the thrombotic basis of ACS and the role of platelet inhibition in preventing recurrent cardiovascular events after PCI.
Differentiate ticagrelor, clopidogrel and prasugrel according to activation, receptor binding, onset, potency, reversibility, variability and important adverse effects.
Compare the ischaemic and bleeding consequences of longer DAPT with strategies that withdraw aspirin and continue P2Y12 inhibitor monotherapy.
Interpret the major findings of TWILIGHT, TICO, T-PASS and ULTIMATE-DAPT as they relate to ticagrelor monotherapy after PCI.
Apply the 2025 ACC/AHA ACS recommendations on 12-month DAPT and transition to ticagrelor monotherapy at or after one month.
Identify patients who may be suitable for ticagrelor monotherapy and those who require caution because of high ischaemic risk, intolerance, poor adherence or anticoagulation needs.
Guardians of the Heart: "Optimizing Antiplatelet Therapy in Acute Coronary Syndrome"
CME MCQs
.jpg)
